Document Detail


Recombinant high-density lipoprotein formulations.
MedLine Citation:
PMID:  21057986     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
High-density lipoprotein cholesterol (HDL-C) has emerged as a biomarker of residual cardiovascular disease (CVD) risk in high-risk patients treated with low-density lipoprotein cholesterol (LDL-C)-lowering therapies inclusive of inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase. The evidence for increasing low levels of HDL-C is sparse, and the available data are confounded by metabolic interactions between elevated very low-density lipoprotein (VLDL) and LDL particle concentrations. Despite these limitations, there has been widespread interest in novel strategies that target HDL. One such path has been the development of recombinant HDL formulations that mimic the pre-beta fraction of native HDL, which is the main HDL subclass that mediates cholesterol efflux from lipid-laden macrophages. Various recombinant HDL formulations (apolipoprotein A-1 [apoA-1]-bound phospholipid disks or delipidated HDL particles, mutant apoA-1 proteins, and apoA-1 mimetic peptides) have been investigated in animal studies and some human trials. However, these HDL-modifying therapies require evaluation in clinical trials of atherosclerosis and CVD events. This review presents our current knowledge on novel recombinant therapies, and their future prospects to mitigate atherosclerotic CVD events.
Authors:
Esad Vucic; Robert S Rosenson
Related Documents :
7965656 - Decreased toxicity of liposomal amphotericin b due to association of amphotericin b wit...
2010736 - Accuracy and precision of hdl cholesterol measurements using an office chemistry analyzer.
8138276 - Distribution of cholesterol in hdl and its subfractions in patients with coronary ather...
8876936 - Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein su...
36 - The effects of processing of barley-based supplements on rumen ph, rate of digestion of...
4370656 - Mechanisms for development of diabetic hypertriglyceridemia in streptozotocin-treated r...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  13     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  81-7     Citation Subset:  IM    
Affiliation:
Translational and Molecular Imaging Institute, Imaging Science Laboratories, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Age estimation and the medial clavicular epiphysis: analysis of the age of majority in an Australian...
Next Document:  Markers of thrombin generation during resurfacing and noncemented total hip arthroplasty: a pilot st...